{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:24:58Z","timestamp":1787225098377,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["JR24\/00028"],"award-info":[{"award-number":["JR24\/00028"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CM23\/00215"],"award-info":[{"award-number":["CM23\/00215"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["JR24\/00028"],"award-info":[{"award-number":["JR24\/00028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CM23\/00215"],"award-info":[{"award-number":["CM23\/00215"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.04.025","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:35:07Z","timestamp":1778578507000},"page":"988.e1-988.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secondary Malignancies After Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-3656","authenticated-orcid":false,"given":"Pedro","family":"Asensi Cant\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6723","authenticated-orcid":false,"given":"Miguel","family":"Mansilla-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Balaguer-Rosell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-527X","authenticated-orcid":false,"given":"Juan","family":"Eir\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mart\u00ednez Campuzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Louro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-6490","authenticated-orcid":false,"given":"Luis","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3694-7157","authenticated-orcid":false,"given":"Luis","family":"Benlloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-2905","authenticated-orcid":false,"given":"In\u00e9s","family":"G\u00f3mez-Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Solves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"De la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.04.025_bib0001","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.025_bib0002","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.025_bib0003","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.bbmt.2014.07.009","article-title":"Second solid cancers after allogeneic hematopoietic cell transplantation using reduced intensity conditioning","volume":"20","author":"Ringd\u00e9n","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.025_bib0004","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2017.02.015","article-title":"Long-term incidence of secondary malignancies after allogeneic hematopoietic cell transplantation: a single-center experience","volume":"23","author":"Michelis","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.025_bib0005","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/bloodadvances.2019000839","article-title":"Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases","volume":"4","author":"Kahn","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.025_bib0006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","article-title":"Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients","volume":"5","author":"Tichelli","year":"2018","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2026.04.025_bib0007","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/bloodadvances.2018020966","article-title":"Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation","volume":"2","author":"Inamoto","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.025_bib0008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors","volume":"21","author":"Baker","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.025_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamadermatol.2015.3902","article-title":"Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study","volume":"152","author":"Omland","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.025_bib0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdt558","article-title":"Continuing increased risk of oral\/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease","volume":"25","author":"Atsuta","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.025_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1704706","article-title":"Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation","volume":"35","author":"Hasegawa","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.025_bib0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bmt.1704674","article-title":"Nonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: incidence and molecular monitoring","volume":"34","author":"Au","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.025_bib0013","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.1994.12.10.2187","article-title":"Secondary malignancies after bone marrow transplantation in adults","volume":"12","author":"Lowsky","year":"1994","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.025_bib0014","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41409-024-02319-x","article-title":"Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience","volume":"59","author":"Sanz","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.025_bib0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35696","article-title":"Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study","volume":"131","author":"Lloret-Madrid","year":"2025","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.025_bib0017","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/CCO.0000000000000119","article-title":"Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation","volume":"26","author":"Sanz","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.025_bib0018","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/10428194.2018.1474462","article-title":"Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation","volume":"60","author":"Romero","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.04.025_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.06.031","article-title":"Incidence and risk factors of skin cancer and preneoplastic lesions after autologous and allogeneic hematopoietic cell transplantation","author":"Mansilla-Polo","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.025_bib0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41409-024-02391-3","article-title":"Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide","volume":"59","author":"Asensi Cant\u00f3","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.025_bib0021","article-title":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide","author":"Asensi Cant\u00f3","year":"2026","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.025_bib0022","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","article-title":"Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors","volume":"55","author":"Montoro","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.jtct.2026.04.025_bib0023","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/bmt.2015.63","article-title":"Secondary solid cancer screening following hematopoietic cell transplantation","volume":"50","author":"Inamoto","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.025_bib0024","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41409-023-02190-2","article-title":"International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update","volume":"59","author":"Rotz","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.025_bib0025","series-title":"(ICD-O-4): An overview","article-title":"The International Classification of Diseases for Oncology","author":"Znaor","year":"2026"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.025_bib0026","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.025_bib0027","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.025_bib0028","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbmt.2010.10.010","article-title":"Donor cell leukemia: a review","volume":"17","author":"Wiseman","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.025_bib0029","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41375-018-0218-6","article-title":"European experience and risk factor analysis of donor cell-derived leukaemias\/MDS following haematopoietic cell transplantation","volume":"33","author":"Engel","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.025_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.025_bib0031","first-page":"829","article-title":"Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced","volume":"27","author":"Shimoni","year":"2012","journal-title":"Leuk 2013 274."},{"issue":"3","key":"10.1016\/j.jtct.2026.04.025_bib0032","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ejh.14355","article-title":"Secondary malignancies after autologous stem cell transplantations in patients with malignant lymphoma and multiple myeloma","volume":"114","author":"Metzner","year":"2025","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.025_bib0033","article-title":"Risk of subsequent malignant neoplasms following hematopoietic stem cell transplantation with total body irradiation or total marrow irradiation: insights from early follow-up","volume":"28","author":"Ladbury","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.025_bib0034","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000654","article-title":"Second solid cancers after hematopoietic stem cell transplantation: active surveillance during long-term follow-up","volume":"5","author":"Lupo-Stanghellini","year":"2021","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.025_bib0035","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ijc.34115","article-title":"Risk of secondary nonhematologic malignancies after allogeneic stem cell transplantation: a nationwide case-control cohort study","volume":"151","author":"Park","year":"2022","journal-title":"Int J cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.025_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-024-02520-8","article-title":"Secondary solid malignancies in long-term survivors after total body irradiation","volume":"19","author":"Gruber","year":"2024","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.025_bib0037","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41409-024-02474-1","article-title":"Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis","volume":"60","author":"Meyer","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.04.025_bib0038","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.1182\/blood-2024-202626","article-title":"Assessment of secondary malignancies after allogeneic hematopoietic cell transplant when comparing treatment with and without post-transplant cyclophosphamide","volume":"144","author":"Nurse","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.025_bib0039","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bjh.70006","article-title":"Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation","volume":"207","author":"Desai","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.04.025_bib0040","doi-asserted-by":"crossref","unstructured":"Krishnan AY, Mei M, Sun CL, et al. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. 2013.","DOI":"10.1016\/j.bbmt.2012.09.023"},{"key":"10.1016\/j.jtct.2026.04.025_bib0041","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.025_bib0042","doi-asserted-by":"crossref","first-page":"205.e1","DOI":"10.1016\/j.jtct.2023.06.015","article-title":"Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation","volume":"30","author":"Yalniz","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.025_bib0043","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/ajh.27452","article-title":"Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"99","author":"Al Hadidi","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.025_bib0044","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/bmt.2015.203","article-title":"Survival of patients who develop solid tumors following hematopoietic stem cell transplantation","volume":"51","author":"Ehrhardt","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600312X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600312X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:12:18Z","timestamp":1785701538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600312X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S266663672600312X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Malignancies After Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}